Many cancer medications fail to effectively target the most commonly mutated cancer genes in humans, called RAS. Now, scientists have uncovered details into how normal RAS interacts with mutated RAS ...
K.W. Wood, C. Sarnecki, T.M. Roberts, J. Blenis, "ras mediates nerve growth factor receptor modulation of three signal- transducing protein kinases: MAP kinase, Raf-1 ...
Highlights: The study examines anti-RAS activity in a series of RAS inhibitors with a predicted unique interaction region. The compounds, in development at Qualigen Therapeutics, bind wild type KRAS ...
Stopping RAS inhibitors after eGFR decline may raise risk of kidney failure and death. Learn more about this new study.
LA JOLLA--(May 18, 2020) Many cancer medications fail to effectively target the most commonly mutated cancer genes in humans, called RAS. Now, Salk Professor Geoffrey Wahl and a team of scientists ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results